1. Characteristic requirement 1: device containing polymerizing drug, including: (1) polyurethane copolymer in whole block, generated when reacting together: (a) nitrous oxide (TAR)；(b) A dysfunctional compound； (c) a dysfunctional isocyanate； and (d) a monolithic copolymer of police blocks (TAR)；And (II) quinine or a pharmaceutically acceptable salt as an active pharmaceutical preparation. 13. Claim 2: the polymeric drug device in claim 1, wherein nitrous oxide (TAR) is a polyethylene glycol (PEG) or a polypropylene glycol (PPG). 6. Characteristic 6: any of the above-mentioned multi-functional drug devices, in which the dysfunctional compounds are selected from diodes, diamonds and amino alcohol groups； the optional diodes are c8323-c83322； 8320；O the dysfunctional compounds were selected from the following groups: 1,4-butane； 1,5-pentabromodiphenyl ether； 1,6-hexabromodiphenyl ether； 1,10-butanediol； 1,12-dodecane； 1,16-hexabromodiphenyl ether. Claim 10: any polymer drug device according to the above requirements, in which (a) can be obtained by the overall reaction of the component,(b)(c) (d) can be used in the presence of catalyst； in the presence of catalyst, an iron chloride and / or catalyst based on sulfur dioxide can be used as catalyst. Claim 11: any polyurethane pharmaceutical device unit in the above requirements, wherein the polyurethane pharmaceutical device unit includes one or more polyurethane group copolymers, and the main or each polyurethane group copolymer reacts as follows: (a) Nitrous oxide (TAR)；(b) A dysfunctional compound； (c) a dysfunctional isocyanate； and (d) a monolithic copolymer of nitrous oxide (pitch) blocks. Claim 17: any polymerized drug device according to the above requirements, i.e. the shape of the polymerized drug device is a ring inserted and / or implanted into the vagina point. Claim 23: any polymeric drug device unit of the above requirements, wherein quinine or pharmaceutically acceptable table salt is prepared from one
